Definium Therapeutics reports positive Phase 3 EMERGE topline results for DT120 orally disintegrating tablet in major depressive disorder with rapid symptom improvement

Definium Therapeutics reports positive topline findings from the Phase 3 EMERGE study of DT120, an orally disintegrating tablet being developed for major depressive disorder. The central claim is that DT120 met key study goals and showed rapid improvement in depressive symptoms, positioning the program as a late-stage clinical candidate in a large psychiatric indication. The study centers on a novel tablet formulation designed for oral disintegration rather than conventional swallowing, which suggests an emphasis on ease of administration and potentially faster onset. Positive Phase 3 results usually indicate statistically meaningful benefit and a safety profile consistent enough to support regulatory planning, investor attention, and possible commercialization steps. Major depressive disorder remains a high-burden condition with demand for faster-acting and more practical treatments. If the full dataset confirms the topline outcome, DT120 could strengthen Definium's position in the neuropsychiatric drug development landscape and shape next steps with regulators, partners, and prescribers.